Phase 3 study of Levadex for the acute treatment of migraines - MPR
Links shared publicly online about this topic.
- 636total visits
Phase 3 study of Levadex for the acute treatment of migraines - MPR
empr.com —
View full resource at empr.com
Tags: Migraine, Migraine Medication, Headache, Vascular Headache, Pharma, Phase 3 Clinical Trial, News
Most Recently Shared on December 22, 2010 at 5:02 pm By:
MPR News: Phase 3 study of Levadex for the acute treatment of migraines: MAP Pharmaceuticals announced completio... http://bit.ly/gGSzSK
NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy In Acute Migraine
medicalnewstoday.com — “NeurAxon, Inc., announced today Phase 2 clinical study results for NXN-188, a novel, first-in-class treatment with the potential to raise the current standard of care in acute migraine. NXN-188 i” View full resource at medicalnewstoday.com
Most Recently Shared on November 1, 2010 at 12:05 pm By:
NeurAxon Announces NXN-188 Phase 2 Data Demonstrating Efficacy In Acute Migraine http://mnt.to/3LMs #headache #migraine
MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial
news-medical.net — “MAP Pharmaceuticals, Inc. today announced that the Company initiated a trial to compare the pharmacokinetics (PK), safety and metabolic profiles of LEVADEX" orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.” View full resource at news-medical.net
Most Recently Shared on February 16, 2010 at 1:02 pm By:
MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial: MAP Pharmaceuticals, Inc. today announced... http://bit.ly/cQAyXU
Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA
news-medical.net — “MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study” View full resource at news-medical.net
Most Recently Shared on January 12, 2010 at 6:52 am By:
Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA: MAP Pharmaceuticals, Inc. today a... http://bit.ly/5SILup
Novel, Orally Inhaled Migraine Therapy Is Effective, Study Shows
sciencedaily.com — “A new study shows an investigational, orally-inhaled therapy is effective in treating migraines. The multi-center, phase three FREEDOM-301 trial for the orally-inhaled migraine therapy, LEVADEX, shows study participants had significant relief from symptoms such as pain, nausea and light and sound sensitivity when compared to placebo treatment.” View full resource at sciencedaily.com
Most Recently Shared on September 14, 2009 at 1:20 am By:
Study Shows Novel, Orally Inhaled Migraine Therapy Is Effective http://bit.ly/1ypL3
Advertisement
